Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.
Patricia L. Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy. Kropf said decitabine is currently the standard of care in AML and MDS.
Kropf said her study treated patients with decitabine as a single agent, decitabine with carboplatin and decitabine with arsenic. She said the arm of the study that treated patients with decitabine and arsenic produced significantly better response rates than the other two arms, especially in newly-diagnosed AML. She added that there was no difference in toxicity between the three arms.
Resistance Mutations Develop Differently After Noncovalent BTK Therapy in CLL
May 14th 2025During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression after receiving pirtobrutinib for BTK inhibitor–pretreated chronic lymphocytic leukemia.
Read More
Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery
April 30th 2025Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.
Read More
